Helix Peptide Opens New GMP Suite in Cambridge
Our expanded manufacturing facility adds 12,000 sq ft of GMP-grade cleanroom capacity to support growing API demand.
A Major Milestone for Helix Peptide
Helix Peptide is proud to announce the commissioning of our second GMP manufacturing suite at our Cambridge headquarters. The new facility represents a significant investment in peptide API production capacity and quality infrastructure.
What the Expansion Includes
- 12,000 square feet of ISO Class 7 and Class 8 cleanroom space
- Three additional SPPS synthesis lines with automated cleavage and purification
- A dedicated QC laboratory with UPLC-MS, HPLC, and Karl Fischer moisture analysis
- Expanded cold-chain storage with redundant monitoring systems
Why It Matters for Our Partners
Institutional buyers and pharmaceutical partners have increasingly requested larger batch sizes and faster turnaround on GMP-grade peptides. This expansion allows Helix Peptide to:
- Reduce lead times on catalog GMP products by up to 30%
- Accept custom synthesis projects up to kilogram scale
- Offer dedicated project managers for multi-phase API programs
"This facility reflects our commitment to being a long-term manufacturing partner, not just a catalog supplier." — Dr. Elena Vasquez, VP of Operations
Next Steps
The new suite is currently undergoing IQ/OQ/PQ validation. We expect full GMP release capability by Q4 2025. Existing customers can contact their account manager to discuss capacity allocation.
For facility tours and audit scheduling, reach out to hello@helixpeptide.com.